Jiang L, Thall P, Yan F, Kopetz S, Yuan Y
Clin Trials. 2023; 20(5):486-496.
PMID: 37313712
PMC: 10504821.
DOI: 10.1177/17407745231176445.
Grayling M, Dimairo M, Mander A, Jaki T
J Natl Cancer Inst. 2019; 111(12):1255-1262.
PMID: 31218346
PMC: 6910171.
DOI: 10.1093/jnci/djz126.
Blum K, Polley M, Jung S, Dockter T, Anderson S, Hsi E
Cancer. 2019; 125(19):3378-3389.
PMID: 31174236
PMC: 6744328.
DOI: 10.1002/cncr.32289.
Vanderbeek A, Ventz S, Rahman R, Fell G, Cloughesy T, Wen P
Neuro Oncol. 2019; 21(10):1239-1249.
PMID: 31155679
PMC: 6784282.
DOI: 10.1093/neuonc/noz097.
Chen D, Huang P, Lin H, Chiappori A, Gabrilovich D, Haura E
Oncotarget. 2017; 8(51):88376-88385.
PMID: 29179442
PMC: 5687612.
DOI: 10.18632/oncotarget.19088.
Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints.
Jiang W, Wick J, He J, Mahnken J, Mayo M
J Biopharm Stat. 2017; 28(5):824-839.
PMID: 29172970
PMC: 7182359.
DOI: 10.1080/10543406.2017.1402779.
Exploratory trials in mental health: anything to learn from other disciplines?.
Trelle S
Evid Based Ment Health. 2017; 20(1):21-24.
PMID: 28073811
PMC: 10688417.
DOI: 10.1136/eb-2016-102581.
Statistical evaluation of the use of concurrent controls in treatment screening studies.
Carter R, Shi Q
Clin Transl Sci. 2013; 6(4):323-30.
PMID: 23919371
PMC: 3740457.
DOI: 10.1111/cts.12042.
Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.
Iclozan C, Antonia S, Chiappori A, Chen D, Gabrilovich D
Cancer Immunol Immunother. 2013; 62(5):909-18.
PMID: 23589106
PMC: 3662237.
DOI: 10.1007/s00262-013-1396-8.
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.
Wolpin B, OReilly E, Ko Y, Blaszkowsky L, Rarick M, Rocha-Lima C
Ann Oncol. 2013; 24(7):1792-1801.
PMID: 23448807
PMC: 3716216.
DOI: 10.1093/annonc/mdt066.
Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II?.
ODonnell P, Stadler W
Clin Cancer Res. 2012; 18(10):2809-16.
PMID: 22427349
PMC: 3354016.
DOI: 10.1158/1078-0432.CCR-11-2445.
Randomized phase II trials: time for a new era in clinical trial design.
Mandrekar S, Sargent D
J Thorac Oncol. 2010; 5(7):932-4.
PMID: 20581575
PMC: 2941394.
DOI: 10.1097/JTO.0b013e3181e2eadf.
Current issues in oncology drug development, with a focus on Phase II trials.
Sargent D, Taylor J
J Biopharm Stat. 2009; 19(3):556-62.
PMID: 19384696
PMC: 4112076.
DOI: 10.1080/10543400902802474.
Randomized phase II designs.
Rubinstein L, Crowley J, Ivy P, LeBlanc M, Sargent D
Clin Cancer Res. 2009; 15(6):1883-90.
PMID: 19276275
PMC: 3774021.
DOI: 10.1158/1078-0432.CCR-08-2031.
